Previous 10 | Next 10 |
- Numerous abstracts, including 7 oral presentations, highlighting data for ruxolitinib, parsaclisib, tafasitamab and ponatinib to be exhibited Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at th...
Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is $0.76 (-7.3% Y/Y) and the consensus Revenue Estimate is $622.48M (+12.9% Y/Y).Over the last 2 years, INCY has beaten EPS estimates 88% of the time and ...
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis Latest long-term safety and efficacy data on Olumiant reinforce the medicine's potential to help people living with rheumatoid arthritis (RA) PR Newswire INDIANAPOLIS, Nov. 2, 2...
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis - Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial - Baricitinib was recently approved by the European Commiss...
- Incyte placed in the top three for third consecutive year Incyte (Nasdaq:INCY) today announced that the company has again been named a top biopharma employer by Science magazine through its Top Employers Survey of the global pharmaceutical and biotech industry. This ye...
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata - Data support baricitinib's ongoing Phase 3 program and potential to be the first approved medicine for people living with alopecia areata (AA) ...
- Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch - Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep as measured by the PROM...
The Health Canada accepts for review Incyte's ([[INCY]] +0.2%) marketing application seeking approval of pemigatinib as a treatment of previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusion.Pemigatinib is...
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma Canada NewsWire MONTREAL, Oct. 26, 2020 MONTREAL , Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...